Synlogicy summarized accomplishments for 2023 and anticipated key milestones for 2024. 2023 Program & Corporate Milestones: Labafenogene marselecobac, a potential treatment for PKU: Initiation of Synpheny-3, a global, pivotal Phase 3 study evaluating the efficacy and safety of labafenogene marselecobac as a potential treatment for PKU; Positive results from Synpheny-1 Phase 2 study in patients with PKU presented; Received multiple significant regulatory designations; Granted U.S. Patent, specifically covering the mutant PAL enzyme expressed by labafenogene marselecobac and extending patent term exclusivity to 2041. Anticipated Milestones: H1 2024: Data monitoring committee review of initial subset of Synpheny-3 data, potentially supporting study expansion to include 12- to 17 year-olds; H2 2024: Completion of Synpheny-3 full study enrollment; H1 2025: Top-line data for Synpheny-3
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SYBX:
- Synlogic Announces Contract with the Air Force Research Lab
- Synlogic awarded $1M subcontract with Air Force Research Lab
- Synlogic initiated with bullish view at Alliance Global Partners, here’s why
- Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Synlogic expects cash to fund operations into 1H25
